RecruitingPhase 2NCT06317662
Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
Sponsor: National Cancer Institute (NCI)
Akron, OH · Cincinnati, OH · Cleveland, OH · +112 more sites